Crispr Therapeutics announced the hiring and appointment of Raju Prasad as CFO, effective March 14. He joins the company from William Blair & Company, where he served as a partner and senior equity research analyst covering cell therapy, gene therapy, and gene editing companies. Prasad succeeds Brendan Smith, who is leaving the company to pursue external opportunities.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Announces Transition of Chief Financial Officer
- Baird starts Crispr at Neutral with strong launch priced in
- Crispr Therapeutics initiated with a Neutral at Baird
- Crispr Therapeutics price target lowered to $102 from $110 at Oppenheimer
- Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y
